Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
288 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cognitive Impairment - Pipeline Review, H2 2016', provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects - The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Cognitive Impairment Overview 7 Therapeutics Development 8 Cognitive Impairment - Therapeutics under Development by Companies 10 Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 14 Cognitive Impairment - Pipeline Products Glance 15 Cognitive Impairment - Products under Development by Companies 19 Cognitive Impairment - Products under Investigation by Universities/Institutes 26 Cognitive Impairment - Companies Involved in Therapeutics Development 27 Cognitive Impairment - Therapeutics Assessment 80 Drug Profiles 93 Cognitive Impairment - Dormant Projects 255 Cognitive Impairment - Discontinued Products 263 Cognitive Impairment - Product Development Milestones 264 Appendix 274
List of Tables
Number of Products under Development for Cognitive Impairment, H2 2016 21 Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016 22 Number of Products under Development by Companies, H2 2016 23 Number of Products under Development by Companies, H2 2016 (Contd..1) 24 Number of Products under Development by Companies, H2 2016 (Contd..2) 25 Number of Products under Development by Companies, H2 2016 (Contd..3) 26 Number of Products under Investigation by Universities/Institutes, H2 2016 27 Comparative Analysis by Late Stage Development, H2 2016 28 Comparative Analysis by Clinical Stage Development, H2 2016 29 Comparative Analysis by Early Stage Development, H2 2016 30 Comparative Analysis by Unknown Stage Development, H2 2016 31 Products under Development by Companies, H2 2016 32 Products under Development by Companies, H2 2016 (Contd..1) 33 Products under Development by Companies, H2 2016 (Contd..2) 34 Products under Development by Companies, H2 2016 (Contd..3) 35 Products under Development by Companies, H2 2016 (Contd..4) 36 Products under Development by Companies, H2 2016 (Contd..5) 37 Products under Development by Companies, H2 2016 (Contd..6) 38 Products under Investigation by Universities/Institutes, H2 2016 39 Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016 40 Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2016 41 Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016 42 Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 43 Cognitive Impairment - Pipeline by Astellas Pharma Inc., H2 2016 44 Cognitive Impairment - Pipeline by AstraZeneca Plc, H2 2016 45 Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016 46 Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2016 47 Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2016 48 Cognitive Impairment - Pipeline by Cardax, Inc., H2 2016 49 Cognitive Impairment - Pipeline by Cerecor Inc., H2 2016 50 Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016 51 Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H2 2016 52 Cognitive Impairment - Pipeline by Confluence Pharmaceuticals LLC, H2 2016 53 Cognitive Impairment - Pipeline by Coronis Partners Ltd., H2 2016 54 Cognitive Impairment - Pipeline by Cortice Biosciences, Inc., H2 2016 55 Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016 56 Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016 57 Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016 58 Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2016 59 Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016 60 Cognitive Impairment - Pipeline by H. Lundbeck A/S, H2 2016 61 Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H2 2016 62 Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016 63 Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 64 Cognitive Impairment - Pipeline by Iproteos S.L., H2 2016 65 Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016 66 Cognitive Impairment - Pipeline by Luc Therapeutics, Inc., H2 2016 67 Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2016 68 Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016 69 Cognitive Impairment - Pipeline by Neuralstem, Inc., H2 2016 70 Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016 71 Cognitive Impairment - Pipeline by NLS Pharma Group, H2 2016 72 Cognitive Impairment - Pipeline by Octapharma AG, H2 2016 73 Cognitive Impairment - Pipeline by Omeros Corporation, H2 2016 74 Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016 75 Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016 76 Cognitive Impairment - Pipeline by Pfizer Inc., H2 2016 77 Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 78 Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016 79 Cognitive Impairment - Pipeline by Saniona AB, H2 2016 80 Cognitive Impairment - Pipeline by SeneXta Therapeutics SA, H2 2016 81 Cognitive Impairment - Pipeline by Shire Plc, H2 2016 82 Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 83 Cognitive Impairment - Pipeline by Spherium Biomed S.L., H2 2016 84 Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 85 Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016 86 Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 87 Cognitive Impairment - Pipeline by Tetra Discovery Partners LLC, H2 2016 88 Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016 89 Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H2 2016 90 Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2016 91 Cognitive Impairment - Pipeline by Virogenomics BioDevelopment, Inc., H2 2016 92 Assessment by Monotherapy Products, H2 2016 93 Number of Products by Stage and Target, H2 2016 95 Number of Products by Stage and Mechanism of Action, H2 2016 99 Number of Products by Stage and Route of Administration, H2 2016 103 Number of Products by Stage and Molecule Type, H2 2016 105 Cognitive Impairment - Dormant Projects, H2 2016 268 Cognitive Impairment - Dormant Projects (Contd..1), H2 2016 269 Cognitive Impairment - Dormant Projects (Contd..2), H2 2016 270 Cognitive Impairment - Dormant Projects (Contd..3), H2 2016 271 Cognitive Impairment - Dormant Projects (Contd..4), H2 2016 272 Cognitive Impairment - Dormant Projects (Contd..5), H2 2016 273 Cognitive Impairment - Dormant Projects (Contd..6), H2 2016 274 Cognitive Impairment - Dormant Projects (Contd..7), H2 2016 275 Cognitive Impairment - Discontinued Products, H2 2016 276
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
